TyRx Pharma Inc., a Monmouth Junction, N.J.-based commercializer of implantable combination drug devices, has raised $25 million.in first-round funding from Clarus Ventures and Pappas Ventures.
TyRx Pharma, Inc., a leader in the commercialization of implantable combination drug-device products, announced today that the Company has raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. In connection with the financing, Jeffrey Leiden, M.D., Ph.D., Managing Director, and Scott Requadt, J.D., MBA, Principal, both of Clarus Ventures, and Arthur Pappas, Managing Partner, Pappas Ventures, will join TyRx's Board of Directors.
“We are pleased to attract new investment from Clarus and Pappas Ventures,” stated William Edelman, TyRx Pharma's Chief Executive Officer. “In January, we announced FDA clearance of the AIGISrx